• Elizabeth Simonsen, Paul Komenda, Blake Lerner, Nicole Askin, Clara Bohm, James Shaw, Navdeep Tangri, and Claudio Rigatto.
• Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
• Am. J. Kidney Dis. 2017 Nov 1; 70 (5): 638-655.

BackgroundUremic pruritus is a common and burdensome symptom afflicting patients with advanced chronic kidney disease (CKD) and has been declared a priority for CKD research by patients. The optimal treatments for uremic pruritus are not well defined.Study DesignSystematic review.Setting & PopulationAdult patients with advanced CKD (stage ≥ 3) or receiving any form of dialysis.Selection Criteria For StudiesPubMed, CINAHL, Embase, International Pharmaceutical Abstracts, Scopus, Cochrane Library, and ClinicalTrials.gov from their inception to March 6, 2017, were systematically searched for randomized controlled trials (RCTs) of uremic pruritus treatments in patients with advanced CKD (stage ≥ 3) or receiving any form of dialysis. 2 reviewers extracted data independently. Risk of bias was assessed using the Cochrane Collaboration risk-of-bias tool.InterventionAny intervention for the treatment of uremic pruritus was included.OutcomesA quantitative change in pruritus intensity on a visual analogue, verbal rating, or numerical rating scale.Results44 RCTs examining 39 different treatments were included in the review. These treatments included gabapentin, pregabalin, mast cell stabilizers, phototherapy, hemodialysis modifications, and multiple other systemic and topical treatments. The largest body of evidence was found for the effectiveness of gabapentin. Due to the limited number of trials for the other treatments included, we are unable to comment on their efficacy. Risk of bias in most studies was high.LimitationsHeterogeneity in design, treatments, and outcome measures rendered comparisons difficult and precluded meta-analysis.ConclusionsDespite the acknowledged importance of uremic pruritus to patients, with the exception of gabapentin, the current evidence for treatments is weak. Large, simple, rigorous, multiarm RCTs of promising therapies are urgently needed.Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

44 keywords...

hide…